SCHEMBL711989

SCHEMBL711989

CCN(C)Cc1nc2ccc3c(c2[nH]1)C(=O)c1ccccc1C3=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.40
KMT2A Q03164 6/20 0.40
ALDH1A1 P00352 5/20 0.40
MEN1 O00255 5/20 0.40
HTT P42858 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40
HPGD P15428 2/20 0.40
POLB P06746 1/20 0.40
MAOA P21397 1/20 0.39
TDP1 Q9NUW8 3/20 0.38
LMNA P02545 2/20 0.38
NSD2 O96028 1/20 0.38
EGFR P00533 1/20 0.38
MAPK1 P28482 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KDM4E B2RXH2 2/20 0.37
RXFP1 Q9HBX9 1/20 0.37
MITF O75030 1/20 0.37
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL712814 0.92 ALDH1A1 (0.38) MAPTKMT2AALDH1A1MEN1HTT
SCHEMBL719982 0.90 KMT2A (0.42) MAPTKMT2AALDH1A1MEN1HTT
SCHEMBL712224 0.90 MAPT (0.41) MAPTKMT2AALDH1A1MEN1HTT
SCHEMBL714445 0.88 MAPT (0.44) MAPTKMT2AALDH1A1MEN1HTT
SCHEMBL10044133 0.88 MAPT (0.43) MAPTKMT2AALDH1A1MEN1HTT
SCHEMBL10071932 0.85 TNKS2 (0.47) MAPTKMT2AALDH1A1MEN1HTT
SCHEMBL10044134 0.84 TDP1 (0.37) MAPTKMT2AALDH1A1MEN1HTT
SCHEMBL712219 0.83 CYP2D6 (0.48) ALDH1A1SMN1; SMN2HPGDPOLBTDP1
SCHEMBL716819 0.81 MMP13 (0.41) KMT2AALDH1A1MEN1HTTSMN1; SMN2
SCHEMBL12261351 0.81 PARP1 (0.51) MAPTKMT2AALDH1A1MEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US claimed
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US disclosed
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US disclosed
US-8124637-B2 Anthra [1, 2-d]imidazole-6,11-dione derivatives, preparation method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2012-02-28 US disclosed
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof NATIONAL DEFENSE MEDICAL CENTER (TW) 2011-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110207719-A1 Novel Anthra [1, 2-d]imidazole-6,11-dione Derivatives, Preparation Method and application thereof TERT, ACIN1, AK2 MAPT 3490/4885KMT2A 452/4885ALDH1A1 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.